Bhageria Industries Ltd
Bhageria Industries Q2 FY22: Revenue ₹141 Cr, PAT ₹15 Cr
Q2 FY22 investor presentation: what the company reported on revenue, margins and projects.
Based on Bhageria Industries Ltd's Q2 FY22 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q2 FY22 Net Sales: Rs 141 crore, up 33.7% YoY from Rs 106 crore in Q2 FY21 (Page 5). Q2 FY22 EBITDA: Rs 26 Cr, up 7% YoY from Rs 25 Cr in Q2 FY21 - Q2 FY22 EBITDA Margin: 18.1%, down from 23.8% in Q2 FY21 - Q2 FY22 PAT: Rs 15 Cr, down 6.6% YoY from Rs 16 Cr in Q2 FY21 - Q2 FY22
From Bhageria Industries Ltd's Q2 FY22 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY22 Net Sales: Rs 141 crore, up 33.7% YoY from Rs 106 crore in Q2 FY21 (Page 5).
- H1 FY22 Net Sales: Rs 254 crore, up 61.1% YoY from Rs 158 crore in H1 FY21 (Page 5).
- Chemical segment Q2 FY22 sales: Rs 134 crore versus Rs 100 crore in Q2 FY21 (Page 5).
- Solar segment Q2 FY22 sales: Rs 6 crore, unchanged YoY (Page 5).
- The presentation mentions "Higher volumes led to increase in revenues by 34% on Y-o-Y basis" for Q2 (Page 5).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Bhageria Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total planned capex of ~Rs. 130 crore funded through internal accruals.
- Specific capex allocations:
- Rs. 46 crore for backward integration (100% incurred).
- Rs. 34 crore for expansion in dye intermediates (100% incurred).
- Rs. 15 crore for manufacturing of pigment intermediates (90% incurred).
- Rs. 35 crore estimated for enhancing power capacities (board approved, timeline not specified).
- Increase power capacity to 8,000 KW at existing facility to cater to increased capacities.
- Manufacture of sulphuric acid & derivatives, margin accretive products J-acid and Tobias acid.
- Exploring new intermediates products.
- Board approved acquisition of 51% equity shares of Bhageria & Jajodia Pharmaceuticals Pvt. Ltd., marking entry into pharma segment.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bhageria Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Bhageria Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹271 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bhageria Industries Ltd's management said in earlier quarters
Frequently Asked Questions
What were Bhageria Industries Ltd Q2 FY22 results?
Q2 FY22 Net Sales: Rs 141 crore, up 33.7% YoY from Rs 106 crore in Q2 FY21 (Page 5). Q2 FY22 EBITDA: Rs 26 Cr, up 7% YoY from Rs 25 Cr in Q2 FY21 - Q2 FY22 EBITDA Margin: 18.1%, down from 23.8% in Q2 FY21 - Q2 FY22 PAT: Rs 15 Cr, down 6.6% YoY from Rs 16 Cr in Q2 FY21 - Q2 FY22
What is Bhageria Industries Ltd share price analysis?
Bhageria Industries Ltd currently shows a neutral. The stock trades at a P/E of 19.7 with a market cap of ₹1,461 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bhageria Industries Ltd planning capital expenditure?
Total planned capex of ~Rs.
Keep Bhageria Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.